Skip to main content
SpringerLink
Log in

US FDA requests warnings for micro-bubble contrast agents

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. FDA.Micro-bubble contrast agents (marketed as Definity (perflutren lipid microsphere) injectable suspension and Optison (perflutren protein-type A microspheres for injection). Internet Document: [3 pages], 12 Oct 2007. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

US FDA requests warnings for micro-bubble contrast agents. React. Wkly. 1174, 3 (2007). https://doi.org/10.2165/00128415-200711740-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711740-00006

Keywords

Search

Navigation